- The multi-year strategic partnership will enable GenesisCare to offer patients greater access to leading technology, with a plan to explore further collaborations to improve cancer diagnosis, treatment and cardiovascular care
- The agreement is valued at more than USD 130 million over the next five years, including imaging technologies, digital solutions, clinical education and services
- Together, GenesisCare and GE Healthcare aim to achieve earlier, faster and more confident cancer diagnosis and more precise intervention and individualiz
For media inquiries, please contact:
Hannah Huntly
Director, External Communications
GE Healthcare
+44 7887 824201
[email protected] Alma Dayawon
+61 4 66507548
[email protected] Bronte Kerr
Media Relations Manager
Genesis Care
+61 411 676 269
[email protected] Angharad Bhardwaj
U.S. Communications Officer
GenesisCare
843-754-2378
[email protected]
business unit
tags
- Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment.
- The two companies will leverage their combined scientific, commercial and market access expertise to work towards a commercial launch.
Chalfont St Giles, UK – October 9th 2019 – GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent.
For media inquiries, please contact:
David MorrisCommunications Director, Pharmaceutical Diagnostics
GE Healthcare
+44 7920591370
[email protected]
Europe/London
business unit
tags
Addis Ababa, Ethiopia -- 6 August 2014 -- Building on a growing footprint in Ethiopia and commitment to supporting the priorities of Ethiopia's public and private healthcare providers, GE today announced a US$500,000 commitment to the Pink Ribbon Red Ribbon (PRRR) interventions in Ethiopia as part of the 'Investing in Our Future' event during the US-Africa Leaders Summit this week in Washington DC. Pink Ribbon Red Ribbon, a public-private partnership whose organizing members include the George W. Bush Institute (GWBI), the U.S.
business unit
tags
ST. LOUIS -- Today at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery* IQ^ PET/CT system, enabling both outstanding image quality and intelligent quantitation, helping physicians deliver the best possible patient outcomes.
business unit
tags
Princeton, NJ -- May 30, 2014 -- Effective from June 1st 2014 and following approval by the US Food and Drug Administration (FDA), GE Healthcare today announced the intent to supply generators for the production of sodium pertechnetate; technetium (Tc99m) injection to its radiopharmacies in the US.
business unit
tags
Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer
ALISO VIEJO, CA, December 9, 2013 -- GE Healthcare today announced results from two studies that show how using the MultiOmyx™ Hodgkin Lymphoma (HL) Profile and an investigational profile for breast cancer may improve assessment of the two diseases in subsets of patients.